Weight in adolescents with type I diabetes mellitus during continuous subcutaneous insulin infusion (CSII) therapy

被引:0
|
作者
Raile, K
Noelle, V
Landgraf, R
Schwarz, HP
机构
[1] Univ Leipzig, Childrens Hosp, Res Lab, D-04317 Leipzig, Germany
[2] Univ Munich, Dept Internal Med, Munich, Germany
[3] Univ Munich, Childrens Hosp, Div Endocrinol & Diabet, D-8000 Munich, Germany
来源
JOURNAL OF PEDIATRIC ENDOCRINOLOGY & METABOLISM | 2002年 / 15卷 / 05期
关键词
continuous subcutaneous insulin infusion (CSII); insulin pump; adolescents; body mass index; weight; type 1 diabetes mellitus;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Continuous subcutaneous insulin infusion (CSII) has become increasingly popular as a form of intensified insulin therapy in adolescents with type 1 diabetes mellitus (DM). One reported drawback was increased weight gain in adolescents after initiation of insulin pump therapy. In a prospective, longitudinal, non-randomized and case controlled study, we followed 12 adolescents (mean age 13.6 yr, 8 males, 4 females) from 6 months before the start of CSH to 12 months on CSII. These 12 adolescents with DM on CSII were matched for age, gender, HbA(1c), duration of DM, and body mass index (BMI) with 12 adolescents who continued on multiple injection therapy (MIT). In addition, six of the 12 adolescents on CSII intended to control their weight by means of the insulin pump. These six vs six adolescents within the CSII group were further analyzed for weight development and eating habits. Clinical indications for CSII were dawn phenomenon, night-time hypoglycemia and patient request for more flexibility in DM management. All patients had been in satisfactory metabolic control on MIT. After 12 months of CSII, the daily insulin requirement remained significantly lower than 18 months before (0.79+/-0.11 vs 1.02+/-27 U/kg/d, p=0.034) and number of daily meals was lower (4.1+/-0.9 vs 6.5+/-0.7, p=0.006). Mean initial HbA(1c), was 7.4% in the MIT and CSII patients, and remained comparable between these two groups. BMI was not different between the CSII and MIT group over the entire study period. However, those adolescents on CSII who intended to control their weight by means of the insulin pump were able to achieve relative weight loss during the first 6 months on CSII. Two patients of the CSII group had one severe hypoglycemic episode with loss of consciousness. In conclusion, CSII does not lead to weight gain by itself, but allows sufficient weight control without a negative effect on metabolic control. The general threat of weight gain in patients who switch to insulin pump therapy must be pointed out, and the role of eating habits and caloric content of food should play a central role in insulin pump educational programs.
引用
收藏
页码:607 / 612
页数:6
相关论文
共 50 条
  • [1] Continuous Subcutaneous Insulin Infusion (CSII) Therapy for Management of Apancreatic Diabetes Mellitus
    Altaf, K.
    Adu, J.
    Morrison, G.
    Nunes, Q. M.
    Halloran, C.
    Neoptolemos, J. P.
    Weston, C. P.
    Sutton, R.
    PANCREAS, 2010, 39 (08) : 1307 - 1307
  • [2] Defining insulin needs by means of continuous subcutaneous insulin infusion (CSII) in type I diabetes mellitus.
    Petraroli, G
    Dani, F
    Grassi, G
    Maghenzani, G
    Monge, L
    Pinach, S
    Benaduce, E
    Carta, Q
    DIABETOLOGIA, 1997, 40 : 1312 - 1312
  • [3] Use of continuous subcutaneous insulin infusion (CSII) therapy in a pediatric type 1 diabetes mellitus population
    Howard, CP
    Pettis, D
    Schurig, JM
    DIABETES, 2000, 49 : A359 - A359
  • [4] BODY WEIGHT CHANGES DURING THE CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII) THERAPY IN ADULT TYPE 1 DIABETES PATIENTS
    Szymanska-Garbacz, E.
    Michalska, K.
    Trzeciak, A.
    Loba, J.
    Czupryniak, L.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2014, 16 : A61 - A61
  • [5] Continuous subcutaneous insulin infusion (CSII) therapy for children and adolescents in routine diabetes care
    Maniatis, AK
    Klingensmith, GJ
    Walravens, PA
    Mowry, CJ
    Chase, HP
    DIABETES, 2000, 49 : A361 - A361
  • [6] Continuous subcutaneous insulin infusion (CSII) in neonatal diabetes mellitus.
    Tubiana-Rufi, N
    Munz-Licha, G
    Polak, M
    Czernichow, P
    DIABETOLOGIA, 1999, 42 : A212 - A212
  • [7] Continuous subcutaneous insulin infusion (CSII) versus multiple insulin injections for type 1 diabetes mellitus
    Misso, M. L.
    Egberts, K. J.
    Page, M.
    O'Connor, D.
    Shaw, J.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2010, (01):
  • [8] CONTINUOUS-SUBCUTANEOUS-INSULIN-INFUSION (CSII) IN THE TREATMENT OF DIABETES-MELLITUS
    PAGANO, G
    TAGLIAFERRO, V
    LORENZATI, R
    PAGANI, A
    LENTI, G
    DIABETOLOGIA, 1981, 21 (03) : 312 - 312
  • [9] Continuous subcutaneous insulin infusion (CSII) in children with type 1 diabetes
    Tamborlane, William V.
    Sikes, Kristin A.
    Steffen, Amy T.
    Weinzimer, Stuart A.
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2006, 74 : S112 - S115
  • [10] Continuous subcutaneous insulin infusion (CSII) in patients with Type 2 diabetes
    Lenhard, MJ
    Maser, RE
    DIABETES, 2001, 50 : A440 - A441